Increasing therapeutic efficacy in MPN
- PMID: 24677402
- DOI: 10.1182/blood-2014-02-554766
Increasing therapeutic efficacy in MPN
Abstract
In this issue of Blood, Bhagwat et al describe an elegant series of experiments showing that genetic deletion in the hematopoietic system of Janus kinase 2 (JAK2) abrogates initiation of myeloproliferative disease and substantial disease regression if deleted once disease is initiated.
Comment on
-
Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms.Blood. 2014 Mar 27;123(13):2075-83. doi: 10.1182/blood-2014-01-547760. Epub 2014 Jan 27. Blood. 2014. PMID: 24470592 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous

